Fig. 2

Variation in CXCL10 and IL6 induction by the pan-ERBB inhibitor, AZD8931, and MEK inhibitor, trametinib, in human HNSCC cell lines. a UMSCC8 and UMSCC25 cells were treated for 1 to 6 days with DMSO, AZD8931 (100 nM) or trametinib (10 nM) and conditioned media was analyzed by ELISA for CXCL10 and IL6. Levels were normalized to total cellular protein and presented as pg/µg protein. The data points represent single determinations at five distinct time points per treatment. b The indicated HNSCC cell lines were treated with DMSO or AZD8931 (100 nM) for 4 days and conditioned media was submitted to ELISA for CXCL10 and IL6. The color bar indicates the expression levels of CXCL10 and IL6 after normalization to cellular protein